神经退行症:2023年更新
1Department of Pathology, Nash Family Department of Neuroscience, Department of Artificial Intelligence & Human Health, Neuropathology Brain Bank & Research CoRE, Ronald M. Loeb Center for Alzheimer's Disease, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Free neuropathology
|September 11, 2023
概括
本综述强调了关键的神经病理学研究,重点关注人类组织研究. 进展包括阿尔茨海默病 (AD) 洞察力,TDP-43机制和神经退行性疾病的冷EM结构.
科学领域:
- 神经科学是一个神经科学.
- 神经病理学神经病理学
- 基因组学就是基因组学.
背景情况:
- 神经病理学领域通过基于人体组织的研究不断进步.
- 了解神经退行性疾病需要不同的方法和疾病类别覆盖.
研究的目的:
- 审查去年进行的十项高影响力神经病理学研究.
- 强调与神经病理学家有关的基于人体组织的研究.
- 涵盖神经退行性疾病研究的广泛范围.
主要方法:
- 综合蛋白质组和转录组分析.
- 低温电子显微镜 (cryo-EM) 用于结构的确定.
- 功能性基因组学和病理解剖学研究.
- 深度学习在神经病理学中的应用.
主要成果:
- 对于渐进的超核性麻的新诊断标准.
- 洞察TARDNA结合蛋白43 (TDP-43) 在阿尔茨海默病 (AD) 和边缘性与年龄相关的TDP-43脑病变 (LATE) 中的作用.
- 冷电磁波检测显示了TDP-43内含物和蛋白粉样蛋白结构中的TMEM106B丝.
- 编目了微质基因表达,阐明了APOE对慢性创伤性脑病变的影响,并检查了勒维体进展途径.
- 深度学习模型应用于衰老的死后大脑.
结论:
- 最近的神经病理学研究为神经退行性疾病机制提供了重要的见解.
- 先进的成像和多omics方法正在彻底改变结构和功能理解.
- 在特定的神经退行性途径中,TDP-43和TMEM106B是关键参与者.
- 未来的研究方向包括整合多学科数据和深度学习以提高诊断能力.
相关概念视频
01:15Parkinson's Disease: Overview
592
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
592
01:15Neurogenesis and Regeneration of Nervous Tissue
856
In the CNS, neurogenesis, the birth of new neurons from stem cells, is limited to the hippocampus in adults. In other regions of the brain and spinal cord, neurogenesis is almost non-existent due to inhibitory influences from neuroglia, especially oligodendrocytes, and the absence of growth-stimulating cues. The myelin produced by oligodendrocytes in the CNS inhibits neuronal regeneration. Furthermore, astrocytes proliferate rapidly after neuronal damage, forming scar tissue that physically...
856
01:26Alzheimer's Disease: Overview
517
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
517
01:22Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212
01:37Neural Regulation
39.5K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.5K
01:29Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K